Every field in your CRM is filled. Every deal has a champion. Your forecast still misses. After analyzing more than 40,000 complex B2B opportunities, here is what your deal health methods cannot measure, the 8 vital signs that actually predict a win, and the criteria to score every deal in your next pipeline review.
You know the meeting. It is the end-of-quarter pipeline review, and on paper everything looks ready. Every opportunity has a named champion. Pain is documented. The economic buyer is identified. The fields are green, the stages are advancing, and the rollup says you will make the number.
Then the quarter closes, and a familiar pattern repeats. A chunk of those “qualified” deals do not go to a competitor. They go nowhere. They close in the one column almost no one forecasts: no decision. Roughly a third of complex B2B deals die there, not because the buyer chose someone else, but because nothing the seller saw on paper was ever real enough to move.
If you lead a sales organization, this is the gap between your forecast and your bank account. If you are a founder still close to the deals, it is the difference between a quarter you can defend to your board and one you have to explain. Either way, the problem is rarely the reps and it is rarely the qualification framework. The problem is what the framework was never built to see.
Let us be fair to the tools that got us here. MEDDPICC, and its predecessor MEDDIC, brought real discipline to enterprise selling. Born at PTC in the mid-1990s, the framework gave sales teams a shared language for deal reviews and a structured way to find gaps. It is far better than gut feel, and its adoption surged for good reason.
But its strongest practitioners are honest about what it is. They describe MEDDIC as an X-ray: it shows you where the gaps are, then leaves you to find a separate treatment. And the most openly acknowledged failure mode in the MEDDICC community is that the framework quietly degrades into a checklist. Reps complete fields. Managers see completed fields. Everyone feels qualified.
That is the trap. A filled-in field feels like progress, but a field is just a claim. The single most important idea in this entire piece is the one your reps already know and your CRM cannot enforce:
MEDDPICC is necessary. It is not sufficient. When we examined how complex B2B deals are actually won and lost, three forces kept deciding outcomes that checklist-style qualification never captures.
Featured Episodes
LISTEN ONSHARE [dipl_list icon_width="21px" _builder_version="4.27.4" _module_preset="default" background_color="#f2f1ef" custom_margin="||10px||false|false" custom_margin_tablet="||0px||false|false" custom_margin_phone="||0px||false|false"...
LISTEN ONSHARE [dipl_list icon_width="21px" _builder_version="4.27.4" _module_preset="default" background_color="#f2f1ef" custom_margin="||10px||false|false" custom_margin_tablet="||0px||false|false" custom_margin_phone="||0px||false|false"...
Urgency, differentiation, and storytelling are not soft extras. They are the three forces that most often separate a deal that closes from a deal that stalls, and they are precisely the three a checklist was never built to score.
SVS8 is the deal health discipline inside the Shared Vision Selling (SVS) process. Across more than 40,000 complex B2B opportunities managed through Shared Vision Selling, we identified the eight data elements that correlate with winning. They are not boxes to tick. They are vital signs: the indicators that reveal whether an opportunity is structurally strong or quietly fragile, the way a clinician reads a pulse and a blood pressure to know if a patient is healthy or in trouble.
The metaphor matters because it changes the job of a pipeline review. You are no longer auditing whether your reps filled in the CRM. You are reading the health of the deal. A deal can be advancing through your stages and still be flatlining on the signs that predict a win.
The eight vital signs, in their fixed order:
Three of those eight have no MEDDPICC equivalent at all, and they map directly to the three blind spots: Insight Stories is storytelling, Why Change Now is urgency, and Why Us is differentiation. The other five sharpen what MEDDPICC already touches by raising the standard of proof.
Every vital sign is scored with three colors, and the scoring is evidence-based, not a feeling. RED means No Confidence: unverified, assumed, or unclear. YELLOW means Progressing: some validation exists, but real risk remains. GREEN means Verified: defensible evidence that withstands leadership scrutiny in any forecast review.
GREEN means the buyer said it, not the rep.
Not when the rep asserts it. Not when the CRM field is full. The buyer has to have said it, done it, or confirmed it. That single rule is what turns a hopeful pipeline into an evidence-based one.
For a head of sales, SVS8 is forecast accuracy and coaching leverage. For a founder, it is something larger.
Early growth-stage selling runs on the founder’s intuition. You can feel which deals are real because you have lived every conversation. The problem is that intuition does not scale, does not transfer to your first sales hires, and cannot be presented to a board. When you start handing deals to a team, the thing you are really trying to transfer is your instinct for which opportunities are healthy. SVS8 externalizes that instinct into eight testable signs. It is your judgment, made teachable.
It also changes the conversation with your board and your investors. “We have strong pipeline” is a claim. “We have eleven deals at GREEN on Coach, Why Change Now, and Decision Process, and here are the four that are still YELLOW and why” is evidence. One gets nodded past. The other earns trust in your number, which at growth stage is currency. A fragile pipeline that looks healthy is the fastest way to lose credibility with the people funding your company, and you usually lose it in a single missed quarter you did not see coming.
Of the eight vital signs, one predicted deal success more than any other: the identification of the right Coach inside the buyer organization. Our standing guidance inside the Shared Vision Selling process is blunt about it. Do not exit Discovery without one.
But this is exactly where most teams fool themselves, and where most inflated forecasts begin. A rep has a contact who takes every meeting, responds quickly, says encouraging things, and genuinely seems to like them. That feels like a champion. It is not. That is a Talker, and the Talker is the single most dangerous contact in your pipeline, because they make your rep feel championed while nothing actually moves.
A Doer is different, and behavior is the only evidence that counts. There are four behavioral tests, and a real Coach passes them through action, not sentiment:
They open doors. They put your rep in front of stakeholders the rep could not reach alone.
They share the inside truth. They reveal internal politics, priorities, and budget realities you could not learn from the outside.
They advocate when you are not there. You find out when a new stakeholder shows up already pre-briefed and favorable, because the Coach made your case in a room you were never in.
They spend political capital. They put their own credibility behind your deal, not just polite encouragement.
Here is the one-line test for every leader to use in a review: your champion likes you, but your Coach is doing something about it. Two or more of those behaviors confirmed by evidence, and you have a Doer worth forecasting on. None of them, and you have a Talker, and an honest review scores that deal RED on Coach no matter how warm the relationship feels.
This is also why two of the eight signs together create the most reliable forecast fiction in B2B selling: a single-threaded deal built on a Talker. One enthusiastic contact, no proof of action, no second relationship. It looks alive in the CRM and it is already dying.
The discipline is only as good as the standard you hold each sign to. The table below is the scoring rubric: the question to ask in your next review, and what each color means. Anything the buyer has confirmed is GREEN. Anything the seller asserts but cannot prove is YELLOW. Anything absent is RED.
| The 8 Vital Signs and the question to ask in your next review | RedNo Confidence | YellowProgressing | GreenVerified |
|---|---|---|---|
01 Coach Do you have an internal advocate who will act, not just agree? | No coach identified. Contact has no real influence. No behind-the-scenes guidance. | Only a Talker: positive but not acting. Not yet shaping internal alignment. Limited insight. | Doer confirmed and engaged. Creates access, drives internal conversations, advocates when the seller is not present. |
02 Insight Stories Have you delivered a peer example that creates the "this is us" moment? | No relevant story selected. Messaging is generic and feature-led. Status quo unchallenged. | Story shared but not buyer-owned. Relevance acknowledged but not anchored. Weak urgency impact. | Story strongly resonates. The buyer repeats it as "this is us" and uses it internally. |
03 SSO Can you state the deal in one sentence: scope, amount, and close date? | No clear SSO. Scope, value, or timing unclear. The opportunity is a wish, not a deal. | SSO drafted but not validated. Value estimated, timing directional only. | SSO confirmed with stakeholders. Solution, value, and close date aligned and shared. |
04 Why Change Now Is urgency defined and quantified? What is the measurable cost of inaction? | No urgency driver. Buyer is "just exploring." No consequence defined for delay. | Pain acknowledged but not quantified. Competing priorities slow momentum. Timing flexible. | A compelling trigger, confirmed and quantified. Cost of inaction is clear, time-bound, and executive-facing. |
05 Why Us Can the buyer articulate why you, not just any vendor? | Buyer sees you as one of many. Evaluation is commoditized or price-driven. No preference expressed. | Differentiation emerging but not owned. Shortlisted but not preferred. Strengths recognized, still compared. | Buyer clearly articulates "why you" in their own words. Criteria favor your proof. Sponsor preference emerging. |
06 Business Case Is the value story financial and operational, and mutually built with the buyer? | No quantified case. Value stays vague. Economic buyer not involved. | Directional ROI model in progress. Assumptions unvalidated. Value discussed but not documented. | Mutually built, defensible case. Financial sponsor aligned. Payback and impact clearly defined and buyer-owned. |
07 Red Flags Have the risks that could kill the deal been surfaced and actively managed? | Risks unknown or ignored. Political, budget, or procurement risk unconfirmed. | Risks identified but mitigation incomplete. Resistance still active. Bottleneck emerging. | Key risks surfaced and managed. Mitigation actively executed with named owners. No unmanaged friction. |
08 Decision Process Do you know who decides, how, and when, with the full approval chain mapped? | Signer and process unclear. Approval path undocumented. Late surprises likely. | Stakeholders mapped but steps fuzzy. Timeline estimated, not validated. | Full chain confirmed: Economic, Technical, User, and Coach roles, approval sequence, and timing, all buyer-confirmed. |
Read across any single deal and a truth emerges that a stage-name never tells you. A Proposal-stage opportunity with two RED vital signs is not a late-stage deal. It is an early-stage deal wearing a late-stage label, and it is exactly the kind that surprises a forecast.
You do not need another framework bolted on top of your process. You need to change what a pipeline review is.
Score every deal against the eight signs, in order, on buyer-confirmed evidence. Not CRM hygiene. Actual things the buyer said or did. The first time you do this honestly, expect a sea of red. That is not failure. That is your pipeline telling the truth for the first time.
Calibrate by stage. A Discovery-stage deal with five RED signs is normal. A Proposal-stage deal with two RED signs is a fiction in your forecast. The gap between the color you expect at a stage and the color you actually have is where deals die silently.
Turn every gap into a next move. This is what makes deal health a practice instead of an audit. Because the eight signs live inside the Shared Vision Selling process, every gap maps to a specific action at a specific stage. No buyer-stated cost of inaction? That is your next Discovery conversation, not a hope you carry to the forecast call. Only a Talker on the inside? Multi-thread before you advance the stage, not after.
When teams adopt this discipline, the change is not that reps work harder. It is that the pipeline tells the truth early enough to act on. When ClearData embedded the Shared Vision Selling process, close rates improved from 23% to 34%, because the deals that were never going to close stopped hiding inside the forecast.
Strong deals are not defined by stage progression. They are defined by the health of the 8 vital signs. Replace optimism with evidence.
If your pipeline reviews are still measuring field completion instead of buyer-confirmed evidence, you do not need more discipline from your reps. You need a different question at the center of every review: not “is this stage advancing,” but “is this deal healthy, and how do we know?” That question, asked honestly, against buyer-confirmed evidence, is the difference between a forecast that looks right and one that actually is.
A fast, comprehensive assessment of your go-to-market motion, including how your team qualifies, scores, and advances deals. Ten minutes, and you will know where your biggest revenue is quietly hiding.
Start the Health Check ›The research behind SVS8 and the Shared Vision Selling process is covered in depth in Reese Gomez's book, Light Your Sales FUSE.
Request a Free Copy ›
Fill in the information below to receive your Customized Account Plan:
Fill in the information below to receive your book.
Fill in the information below to receive your book.
Fill in the information below
Fill in the information below to receive your book.
Please fill in the information below to gain access.
Please fill in the information below to gain access.
Please fill in the information below to gain access.
Please fill in the information below to gain access.
Please fill in the information below to gain access.
Please fill in the information below to gain access.
